Research Project

Project Title:	PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN(RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITHFOCALSEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY
Project Type:	Clinical Trial, Enrolment terminated
Disease group(s):	Hereditary glomerulopathies
Project Summary:	The purpose of this trial is to quantify the anti-proteinuric efficacy and to profile the safety of Sparsentan administration in patients with FSGS.
Lead principal investigator(s):	Loreto Gesualdo, Bari
Co-investigator(s):	L Ricciato, Bari V Pavone, Bari
Project Period:	10/2015 - 02/2026
ClinicalTrials.gov:	NCT01613118